Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalUrologyStress Urinary IncontinenceTrial Update

Study on Tactile Feedback Training for Stress Urinary Incontinence in Pregnant Women

This clinical trial could redefine treatment protocols for stress urinary incontinence in pregnant women, potentially leading to a shift in clinical practice. If tactile feedback training is proven more effective, it may create new market opportunities for therapeutic devices in women's health.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / Stress Urinary Incontinence
Asset: Study
Trial SummaryCLN

Phase III

Urology / Stress Urinary Incontinence

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This clinical trial could redefine treatment protocols for stress urinary incontinence in pregnant women, potentially leading to a shift in clinical practice. If tactile feedback training is proven more effective, it may create new market opportunities for therapeutic devices in women's health.

Why it matters

This clinical trial could redefine treatment protocols for stress urinary incontinence in pregnant women, potentially leading to a shift in clinical practice. If tactile feedback training is proven more effective, it may create new market opportunities for therapeutic devices in women's health.

What changed

Trial Update

Analysis

A clinical trial is evaluating the effectiveness of tactile feedback pelvic floor training compared to traditional methods for managing stress urinary incontinence in pregnant women.

This clinical trial could redefine treatment protocols for stress urinary incontinence in pregnant women, potentially leading to a shift in clinical practice. If tactile feedback training is proven more effective, it may create new market opportunities for therapeutic devices in women's health.

Monitor trial results and publication of findings, particularly regarding the effectiveness of tactile feedback compared to traditional methods.

Related companies & assets

Assets

  • Study →
  • pelvic floor therapy solutions →

Sources & Humanexa intelligence

Source links

  • Study on Tactile Feedback Training for Stress Urinary Incontinence in Pregnant Women ↗

Related Humanexa pages

  • Study on Tactile Feedback Training for Stress Urinary Incontinence in Pregnant Women →

Related signals

Trial SummaryCLN

Phase III

Oncology / NSCLC

Status

Active

Signal Score

8.2

Clinicalhigh signal

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

A novel tumor inflammation score based on Treg/T cell relationships predicts treatment outcomes better than traditional biomarkers in NSCLC.

July 5, 2026Read signal →
Trial SummaryCLN

Phase III

hepatocellular carcinoma (HCC)

Status

Active

Sponsor

oncology therapeutics

Signal Score

8.2

Clinicalhigh signal

CENPI identified as a promoter of hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway

CENPI is linked to hepatocellular carcinoma progression through activation of the PI3K/AKT/mTOR-CDK2 cascade.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.